• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

    1.915 +0.015 (+0.79%)
    Streaming Delayed Price Updated: 12:03 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 496,617
    Open 1.920
    Bid (Size) 1.910 (15)
    Ask (Size) 1.920 (60)
    Prev. Close 1.900
    Today's Range 1.870 - 1.970
    52wk Range 1.700 - 30.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
    Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent. 
    Via Benzinga
    Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -87.21%
    -87.21%
    1 Month
    -29.34%
    -29.34%
    3 Month
    -87.87%
    -87.87%
    6 Month
    -87.85%
    -87.85%
    1 Year
    -93.28%
    -93.28%

    More News

    Read More
    AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Unveiling 6 Analyst Insights On Amylyx Pharma
    Via Benzinga
    AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Kaplan Fox & Kilsheimer LLP Reminds Amylyx (NASDAQ: AMLX) Investors of a Class Action Lawsuit and April 9, 2024 Lead Plaintiff Deadline
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Kaplan Fox & Kilsheimer LLP Reminds Amylyx (NASDAQ: AMLX) Investors of a Class Action Lawsuit and April 9, 2024 Lead Plaintiff Deadline
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    AMLX FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    AMLX DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    AMLX DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via TheNewswire.com
    Topics Lawsuit
    Exposures Financial Legal
    AMLX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.